Carmichael Roberts, PhD
Executive Chairman

Carmichael Roberts is the Executive Chairman of Arsenal Medical and a General Partner at North Bridge Venture Partners. Prior to this role, he co-founded and served as the President and Chief Executive Officer of the Company. Before Arsenal Medical, Carmichael co-founded and served as the President and Chief Executive Officer of Surface Logix, Inc., a drug optimization company. Carmichael has also co-founded and served as a director of several other ventures, including Ancora Pharmaceuticals, Inc., a carbohydrate materials company, Nano-Terra, Inc., an electronics and industrial materials company, and Diagnostics For All, Inc., a non-profit organization that is developing a materials platform to make low cost diagnostics for the poor.

Prior to his entrepreneurial career, Carmichael worked in business development at GelTex Pharmaceuticals, Inc., which was acquired by Genzyme for $1.3 billion. Prior to GelTex, Carmichael was responsible for new product and business development in the Sentry Products Specialty Materials Division of Union Carbide Corporation.

Carmichael received his B.S. and Ph.D. in organic chemistry from Duke University and completed his postdoctoral fellowship at Harvard University. Carmichael also received his M.B.A. from the MIT Sloan School of Management.

George Whitesides, PhD
Woodford L. and Ann A. Flowers University Professor, Harvard University

George M. Whitesides was born August 3, 1939 in Louisville, KY. He received an A.B. degree from Harvard University in 1960 and a Ph.D. from the California Institute of Technology (with J.D. Roberts) in 1964. He was a member of the faculty of the Massachusetts Institute of Technology from 1963 to 1982. He joined the Department of Chemistry of Harvard University in 1982, and was Department Chairman 1986-89, and Mallinckrodt Professor of Chemistry from 1982-2004. He is now the Woodford L. and Ann A. Flowers University Professor.

Robert Langer, DSc
David H. Koch Institute Professor, Massachusetts Institute of Technology

Robert S. Langer is one of 14 Institute Professors (the highest honor awarded to a faculty member) at the Massachusetts Institute of Technology (MIT). Dr. Langer has written approximately 1,050 articles. He also has approximately 750 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 220 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history.

He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 -- 2002 and as its Chairman from 1999-2002.

Dr. Langer has received over 170 major awards including the 2006 United States National Medal of Science; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers and the 2008 Millennium Prize, the world’s largest technology prize. He is the also the only engineer to receive the Gairdner Foundation International Award; 72 recipients of this award have subsequently received a Nobel Prize. Among numerous other awards Langer has received are the Dickson Prize for Science (2002), Heinz Award for Technology, Economy and Employment (2003), the Harvey Prize (2003), the John Fritz Award (2003) (given previously to inventors such as Thomas Edison and Orville Wright), the General Motors Kettering Prize for Cancer Research (2004), the Dan David Prize in Materials Science (2005), the Albany Medical Center Prize in Medicine and Biomedical Research (2005), the largest prize in the U.S. for medical research, induction into the National Inventors Hall of Fame (2006), the Max Planck Research Award (2008) and the Prince of Asturias Award for Technical and Scientific Research (2008). In 1998, he received the Lemelson-MIT prize, the world’s largest prize for invention for being “one of history’s most prolific inventors in medicine.” In 1989 Dr. Langer was elected to the Institute of Medicine of the National Academy of Sciences, and in 1992 he was elected to both the National Academy of Engineering and to the National Academy of Sciences. He is one of very few people ever elected to all three United States National Academies and the youngest in history (at age 43) to ever receive this distinction.

Forbes Magazine (1999) and Bio World (1990) have named Dr. Langer as one of the 25 most important individuals in biotechnology in the world. Discover Magazine (2002) named him as one of the 20 most important people in this area. Forbes Magazine (2002) selected Dr. Langer as one of the 15 innovators world wide who will reinvent our future. Time Magazine and CNN (2001) named Dr. Langer as one of the 100 most important people in America and one of the 18 top people in science or medicine in America (America’s Best). Parade Magazine (2004) selected Dr. Langer as one of 6 “Heroes whose research may save your life.” Dr. Langer has received honorary doctorates from Yale University, the ETH (Switzerland), the Technion (Israel), the Hebrew University of Jerusalem (Israel), the Universite Catholique de Louvain (Belgium), the University of Liverpool (England), the University of Nottingham (England), Albany Medical College, the Pennsylvania State University, Northwestern University and Uppsala University (Sweden). He received his Bachelor’s Degree from Cornell University in 1970 and his Sc.D. from the Massachusetts Institute of Technology in 1974, both in Chemical Engineering.

Terry McGuire
Co-founder of and General Partner, Polaris Venture Partners

Terry McGuire is a co-founder of and general partner of Polaris Venture Partners based in the Boston office. Terry focuses on life sciences investments.

Experience:
Prior to starting Polaris, Terry spent seven years at Burr, Egan, Deleage & Co. investing in early stage medical and information technology companies. Terry began his career in venture capital at Golder, Thoma and Cressey in Chicago.

Boards:
Terry has co-founded three companies: Inspire Pharmaceuticals, AIR (Advanced Inhalation Research, Inc.), and MicroCHIPS.

Terry represents Polaris on the boards of directors of Acceleron Pharma, Adimab, Arsenal Medical, Inc., Cerulean Pharma Inc., Ironwood Pharmaceuticals, Life Line Screening, MicroCHIPS, Inc., Pulmatrix Inc., and Trevena Inc.

He has also served on the boards of Akamai, Aspect Medical Systems, Cubist Pharmaceuticals, deCODE Genetics, GlycoFi, Transform Pharmaceuticals, and Remon Medical Technologies.

Terry serves on the boards of the Thayer School of Engineering, Dartmouth College (Chair); The National Venture Capital Association (Chair); MIT’s The David H. Koch Institute for Integrative Cancer Research, and The Arthur Rock Center for Entrepreneurship at HBS.

Education:
MBA from Harvard Business School. MS in engineering from The Thayer School at Dartmouth College. BS in physics and economics from Hobart College.

Awards:
Terry is a recipient of the Albert Einstein Award for Outstanding Achievement in the Life Sciences, awarded by Forbes/Gottlieb Medical Technology Investor, Harvard MIT Biomedical Engineering Center, the New Jerusalem Foundation, the Jerusalem Development Authority, and Rodman and Renshaw.

Jamie Goldstein
Partner, North Bridge Venture Partners

Jamie Goldstein joined North Bridge Venture Partners in 1998. Prior to joining North Bridge, Jamie co-founded PureSpeech, a venture-backed speech recognition software and applications company targeting service providers and enterprise call centers. Jamie served as Vice President of Sales and Marketing, driving revenue through OEM relationships with leading PC manufacturers and voice services platform providers. PureSpeech was acquired by Voice Control Systems (NASDAQ: VCSI) and subsequently sold to Scansoft (NASDAQ: SSFT).

Before PureSpeech Jamie was an early employee with Symmetrix, a provider of manufacturing execution software that helped old-line manufacturing companies streamline their operations. Symmetrix grew to nearly 200 employees before its acquisition by SAIC.

Jamie’s investment interests are diverse – software, storage, wireless, semiconductor and materials companies. He is a graduate of MIT, 1989 and the Harvard Graduate School of Business Administration, 1994. He is actively involved in the MIT Deshpande Center for Innovation, is a Trustee of the MATCH School (a Boston-area Charter school) and serves on the Board of the New England Venture Capital Association.

Dennis Dougherty
Founding Partner, Intersouth Partners

Dennis Dougherty is the founding partner of Intersouth Partners, the largest venture capital fund in North Carolina. Dennis has worked with young companies from initial investment through public offering. He has served on the boards of 35 companies, including as Chairman for several public companies. He is a founder of the NC Council for Entrepreneurial Development (CED), the largest entrepreneurial support organization in the U.S., and served on the Board of the National Venture Capital Association, the NC State University Seed Fund and the Governor’s Biotechnology Steering Committee for the NC Biotechnology Center.

Prior to starting Intersouth in 1985, Dennis was an office managing partner and head of the small business unit for Touche Ross.

Guido Neels
Managing Director, Essex Woodlands Health Ventures

Guido Neels served as Chief Operating Officer of Guidant Corporation, a world leader in the development of cardiovascular medical products, from May 2004 until retiring in November 2005. He was responsible for the global operations of Guidant's four operating units: Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery, and Endovascular Solutions. From December 2002 to May 2004, he was Group Chairman, Office of the President at Guidant, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. From January 2000 to December 2002, he was President of Guidant for Europe, Middle East, Africa and Canada. He previously served as Vice President of Global Marketing for Vascular Intervention and as Managing Director for German and Central European operations. From 1982 to 1994, until Guidant was spun off as an independent public company from Eli Lilly and Co., Mr. Neels held various general management and sales and marketing positions at Lilly in the U.S. and Europe. From 1972 to 1980, he held positions in information technology, finance and manufacturing at Raychem Corporation in Belgium and the U.S.

Mr. Neels joined Essex Woodlands in August 2006. He has been an independent director with Biopure Corporation since August 2005. He holds Board positions on ROX Medical, Nellix Endovascular, Inc. and Oraya, Inc. as well as Arsenal Medical, EndGenitor Technologies, and Endovascular, Inc. He holds a Master of Business Administration degree from Stanford University and a Business Engineering degree from the University of Leuven in Belgium.